Accepted author manuscript, 597 KB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Licence: CC BY: Creative Commons Attribution 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Electrospun Produced 3D Matrices for Covering of Vascular Stents
T2 - Paclitaxel Release Depending on Fiber Structure and Composition of the External Environment
AU - Kuznetsov, Konstantin
AU - Stepanova, Alena
AU - Kvon , Ren
AU - Douglas, Timothy Edward Lim
AU - Kuznetsov, Nikita
AU - Chernonosova, Vera
AU - Zaporozhchenko, Ivan
AU - Kharkova, Maria
AU - Romanova, Irina
AU - Karpenko, Andrey
AU - Laktionov, Pavel
PY - 2018/11/2
Y1 - 2018/11/2
N2 - Paclitaxel is a natural, highly lipophilic anti proliferative drug widely used in medicine. We have studied the release of tritium-labeled paclitaxel (3H-PTX) from matrices destined for the coating of vascular stents and produced by the electrospinning method from the solutions of polycaprolactone (PCL) with paclitaxel (PTX) in hexafluoisopropanol (HFIP) and/or solutions of PCL with PTX and human serum albumin (HSA) in HFIP or HIFP-dimethyl sulphoxide (DMSO) blend. The release of PTX has been shown to depend on the composition of electrospinning solution, as well as the surrounding medium, particularly the concentration of free PTX and PTX-binding biomolecules present in human serum. It was shown that 3D matrices can completely release PTX without weight loss. Two-phase PTX release from optimized 3D matrices was obtained: ~27% of PTX was released in the first day, another 8% were released over the next 26 days. Wherein ~2.8%, ~2.3%, and ~0.25% of PTX was released on day 3, 9, and 27, respectively. Considering PTX toxicity, the rate of its diffusion through the arterial wall, and the data obtained the minimum cytostatic dose of the drug in the arterial wall will be maintained for at least three months. © 2018 by the authors.
AB - Paclitaxel is a natural, highly lipophilic anti proliferative drug widely used in medicine. We have studied the release of tritium-labeled paclitaxel (3H-PTX) from matrices destined for the coating of vascular stents and produced by the electrospinning method from the solutions of polycaprolactone (PCL) with paclitaxel (PTX) in hexafluoisopropanol (HFIP) and/or solutions of PCL with PTX and human serum albumin (HSA) in HFIP or HIFP-dimethyl sulphoxide (DMSO) blend. The release of PTX has been shown to depend on the composition of electrospinning solution, as well as the surrounding medium, particularly the concentration of free PTX and PTX-binding biomolecules present in human serum. It was shown that 3D matrices can completely release PTX without weight loss. Two-phase PTX release from optimized 3D matrices was obtained: ~27% of PTX was released in the first day, another 8% were released over the next 26 days. Wherein ~2.8%, ~2.3%, and ~0.25% of PTX was released on day 3, 9, and 27, respectively. Considering PTX toxicity, the rate of its diffusion through the arterial wall, and the data obtained the minimum cytostatic dose of the drug in the arterial wall will be maintained for at least three months. © 2018 by the authors.
KW - 3D matrix
KW - Drug release
KW - Electrospinning
KW - Paclitaxel
KW - Polycaprolactone
KW - Body fluids
KW - Controlled drug delivery
KW - Drug dosage
KW - Solvents
KW - Stents
KW - Anti-proliferative
KW - D matrixes
KW - Electrospinning method
KW - External environments
KW - Fiber structures
KW - Human serum albumins
KW - Targeted drug delivery
U2 - 10.3390/ma11112176
DO - 10.3390/ma11112176
M3 - Journal article
VL - 11
JO - Materials
JF - Materials
SN - 1996-1944
IS - 11
M1 - 2176
ER -